Roche introduces new cobas t 411 analyzer for coagulation testing

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its new lab-coagulation solution, the cobas t 411 analyzer, is now available for countries accepting the CE Mark.

The new cobas t 411 analyzer is a stand-alone lab coagulation system that is suitable for low-volume routine testing (up to 120 samples per day). With this launch, Roche has expanded their overall laboratory coagulation offering, giving laboratories further flexibility for their dedicated testing needs.

“We are entering into a new era of coagulation testing for Roche, through expansion of our coagulation solution and we will continue to develop systems which support our customer’s lab efficiency and productivity needs” said Jean-Claude Gottraux, Head of Roche Professional Diagnostics. “The cobas t 411 is the next foundation stone for Roche to become a total solution provider for coagulation testing in both the laboratory and at the Point of Care.”

The new cobas t 411 analyzer will enable customers to optimize their laboratory processes. It achieves this by allowing continuous loading of all samples, reagents and the cuvettes, which hold the required samples and reagents during testing. This will ultimately help reduce workflow interruption. The unique cuvette design, and readiness check prior to measurement, helps improve quality of results. The multimode cap piercing, which recognizes different sample cap types prior to sampling, gives flexibility and convenience. In addition, the analyzer has the highest reagent capacity on the market for reduced hands-on time, compared to other systems offered at low-volume coagulation laboratories.